v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting  
Schedule of information about the Company's single segment

Three Months Ended

March 31, 

2026

  ​ ​ ​

2025

  ​ ​ ​

Revenue

$

10,785

$

10,698

Cost of product revenue

1,329

1,262

Research and development (a)

Direct program expenses

AXPAXLI

42,460

24,647

Other clinical and preclinical programs

758

889

Unallocated expenses

Personnel costs

12,976

8,983

All other costs

1,809

3,255

Selling and marketing (a)

14,075

12,817

General and administrative (a)

11,606

9,661

Facilities (b)

2,270

1,664

Stock-based compensation

15,582

10,456

Depreciation

1,260

981

Interest income

6,050

3,826

Interest expense

(2,777)

(2,984)

Other non-operating items

1,455

(978)

Net loss

$

(88,612)

$

(64,053)

(a)excluding stock-based compensation, depreciation, and facilities expenses
(b)excluding stock-based compensation and depreciation